DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Ozanimod is an investigational drug.
There have been 13 clinical trials for Ozanimod. The most recent clinical trial was a Phase 1 trial, which was initiated on February 27th 2018.
The most common disease conditions in clinical trials are Crohn Disease, Sclerosis, and Multiple Sclerosis. The leading clinical trial sponsors are Celgene and [disabled in preview].
There are eight US patents protecting this investigational drug and one hundred and sixteen international patents.
Recent Clinical Trials for Ozanimod
|Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)||Celgene||Phase 3|
|Drug Interaction Study of the Effect on Cyclosporine on Ozanimod and Major Active Metabolites||Celgene||Phase 1|
|To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis||Celgene||Phase 2/Phase 3|
Top disease conditions for Ozanimod
Top clinical trial sponsors for Ozanimod
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Ozanimod||Start Trial||Kinase inhibitors||Respivert Limited (High Wycombe, Buckinghamshire, GB) Topivert Pharma Limited (London, GB)||Start Trial|
|Ozanimod||Start Trial||Kinase inhibitors||Respivert Limited (N/A) Topivert Pharma Limited (London, GB)||Start Trial|
|Ozanimod||Start Trial||Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis||CELGENE INTERNATIONAL II S RL (Couvet, CH)||Start Trial|
|Ozanimod||Start Trial||Sphingosine pathway modulating compounds for the treatment of cancers||Enzo Biochem, Inc. (New York, NY)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|